ライフサイエンスコーパス: antilymphocyte antibody

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します

1 in the treatment of side effects induced by antilymphocyte antibodies.

2 eived either ganciclovir or acyclovir during antilymphocyte antibody administration.

3 tomegalovirus (CMV) and who are treated with antilymphocyte antibody (ALA) therapy have a high rate o

4 ells (BMC) can prolong allograft survival in antilymphocyte antibody- (ALA) treated recipients.

5 e were fewer episodes of rejection requiring antilymphocyte antibodies and fewer study discontinuatio

6 Antilymphocyte antibodies are widely used to prevent and

7 d previously received at least one course of antilymphocyte antibody as rejection therapy.

8 Fewer CsA-NL patients (5.9%) required antilymphocyte antibody (ATG or OKT-3) therapy for rejec

9 atal grafts could be supported by monoclonal antilymphocyte antibodies, B10.A(5R) recipients were imm

10 The use of antilymphocyte antibodies for induction therapy or for t

11 The use of antilymphocyte antibodies for the treatment of rejection

12 Induction immunosuppression with antilymphocyte antibodies has not been shown to improve

13 , whereas results of studies with monoclonal antilymphocyte antibodies have been disappointing.

14 an adult study population; (2) assessment of antilymphocyte antibodies in the immediate posttransplan

15 renal allografts who did and did not receive antilymphocyte antibodies in the perioperative period we

16 have not shown that the perioperative use of antilymphocyte antibodies (induction therapy) improves s

17 The majority of steroid and antilymphocyte antibody (OKT3 or ATGAM) unresponsive rej

18 The use of antilymphocyte antibody or cyclosporine on day 0/1 decre

19 tors, antitumor necrosis factor-alpha drugs, antilymphocyte antibodies, or chemotherapeutic agents),

20 tithymocyte globulins (AThG) are a subset of antilymphocyte antibody preparations derived from the se

21 pients, and significantly reduces the use of antilymphocyte antibody preparations.

22 ulin (IVIG) in the treatment of steroid- and antilymphocyte antibody-resistant rejection in renal tra

23 IVIG rescue therapy for steroid- or antilymphocyte antibody-resistant rejection is associate

24 therapy rescued three of four patients with antilymphocyte antibody-resistant rejection.

25 ere treated with IVIG to reverse steroid- or antilymphocyte antibody-resistant rejection.

26 Alemtuzumab (Campath-1H) is a powerful antilymphocyte antibody that produces profound and long-

27 were fewer CsA-NL patients (6.9%) requiring antilymphocyte antibody therapy for rejection than in th

28 reduced number of CsA-NL patients requiring antilymphocyte antibody therapy for rejection, fewer Int

29 Antilymphocyte antibody therapy was not used to treat re

30 ravenous ganciclovir for the duration of any antilymphocyte antibody therapy, in our kidney and simul

31 primary CMV infection and in those receiving antilymphocyte antibody therapy.

32 Furthermore, additional antilymphocyte antibody treatment was required to revers

33 Antilymphocyte antibody was required in eight (13%) pati

WebLSDに未収録の専門用語（用法）は "新規対訳" から投稿できます。